Pregnancy rate with 1 week versus 2 weeks of hormonal therapy

Clinical pregnancy rate for frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment - Shorten Time To Pregnancy (STTP)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-000689-13-BE

Enrollment

150

Registered

2018-06-07

Start date

2018-07-11

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfertility in need of IVF and IVF-ICSI treatment MedDRA version: 20.0 Level: LLT Classification code 10042391 Term: Subfertility System Organ Class: 100000004872

Interventions

Trade Name: progynova Product Name: progynova Product Code: RVG 05311. Pharmaceutical Form: Tablet INN or Proposed INN: Estradiol valerate CAS Number: 979-32-8 Other descriptive name: ESTRADIOL VALERA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Women aged =18 and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Body mass index of =18 and = 29 • Previous diagnosis of PCOS/POI • Endometriosis stage 3 and 4 • Previous diagnosis of hydrosalpinx • Systemic diseases such as thyroid dysfunction, unless corrected • History of recurrent implantation failure or recurrent miscar-riage • PGD/PGS cycles • Oocytes donation cycles

Design outcomes

Primary

Measure	Time frame
Secondary Objective: Assess the rate of positive hCG tests, biochemical pregnancy, early pregnancy loss. Furthermore, evaluate the predicatability of pregnancy by the endocrinological profile (estradiol and pro-gesterone levels) within the endometrial preparation and the day of ET. ;Primary end point(s): - Clinical Pregnancy Rate - Miscarriage rate ;Timepoint(s) of evaluation of this end point: at the end of inclusion;Main Objective: Compare the clinical pregnancy rate of a frozen embryo transfer cycle after endometrial preparation of 7 versus 14 days of estradiol valerate treatment	—

Measure

Time frame

Secondary Objective: Assess the rate of positive hCG tests, biochemical pregnancy, early pregnancy loss. Furthermore, evaluate the predicatability of pregnancy by the endocrinological profile (estradiol and pro-gesterone levels) within the endometrial preparation and the day of ET. ;Primary end point(s): - Clinical Pregnancy Rate - Miscarriage rate ;Timepoint(s) of evaluation of this end point: at the end of inclusion;Main Objective: Compare the clinical pregnancy rate of a frozen embryo transfer cycle after endometrial preparation of 7 versus 14 days of estradiol valerate treatment

—

Secondary

Measure	Time frame
Secondary end point(s): Assess the rate of positive hCG tests, biochemical pregnancy, early pregnancy loss. Furthermore, evaluate the predicatability of pregnancy by the endocrinological profile (estradiol and pro-gesterone levels) within the endometrial preparation and the day of ET. ;Timepoint(s) of evaluation of this end point: at the end of inclusion	—

Countries

Belgium

Contacts

Public ContactClinical Trial Information Desk

University hospital Brussel

Studieverpleegkundigen_CRG@uzbrussel.be

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026